These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 22334453)

  • 1. Targeted therapy in the management of advanced gastric cancer: are we making progress in the era of personalized medicine?
    Wong H; Yau T
    Oncologist; 2012; 17(3):346-58. PubMed ID: 22334453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic Profiling of HER2-Positive Gastric Cancer: PI3K/Akt/mTOR Pathway as Predictor of Outcomes in HER2-Positive Advanced Gastric Cancer Treated with Trastuzumab.
    Díaz-Serrano A; Angulo B; Dominguez C; Pazo-Cid R; Salud A; Jiménez-Fonseca P; Leon A; Galan MC; Alsina M; Rivera F; Plaza JC; Paz-Ares L; Lopez-Rios F; Gómez-Martín C
    Oncologist; 2018 Sep; 23(9):1092-1102. PubMed ID: 29700210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted therapy in gastric cancer.
    Thiel A; Ristimäki A
    APMIS; 2015 May; 123(5):365-72. PubMed ID: 25706252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting receptor tyrosine kinases in gastric cancer.
    Morishita A; Gong J; Masaki T
    World J Gastroenterol; 2014 Apr; 20(16):4536-45. PubMed ID: 24782606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway.
    Nahta R; O'Regan RM
    Clin Breast Cancer; 2010 Nov; 10 Suppl 3():S72-8. PubMed ID: 21115425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A systematic review of dual targeting in HER2-positive breast cancer.
    Kümler I; Tuxen MK; Nielsen DL
    Cancer Treat Rev; 2014 Mar; 40(2):259-70. PubMed ID: 24080156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted therapy in advanced gastric carcinoma: the future is beginning.
    Schinzari G; Cassano A; Orlandi A; Basso M; Barone C
    Curr Med Chem; 2014; 21(8):1026-38. PubMed ID: 24304282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted therapy for gastric cancer: Current status and future directions (Review).
    Yuan DD; Zhu ZX; Zhang X; Liu J
    Oncol Rep; 2016 Mar; 35(3):1245-54. PubMed ID: 26718131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular targeted therapy for advanced gastric cancer.
    Kim JG
    Korean J Intern Med; 2013 Mar; 28(2):149-55. PubMed ID: 23525404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A systematic review and meta-analysis of randomized trials on the role of targeted therapy in the management of advanced gastric cancer: Evidence does not translate?
    Ciliberto D; Staropoli N; Caglioti F; Gualtieri S; Fiorillo L; Chiellino S; De Angelis AM; Mendicino F; Botta C; Caraglia M; Tassone P; Tagliaferri P
    Cancer Biol Ther; 2015; 16(8):1148-59. PubMed ID: 26061272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Research status quo and progression in targeted therapy for advanced gastric cancer].
    Feng R; Zhang X; Yang S
    Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Oct; 19(10):1191-1196. PubMed ID: 27781258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Personalizing therapies for gastric cancer: molecular mechanisms and novel targeted therapies.
    Luis M; Tavares A; Carvalho LS; Lara-Santos L; Araújo A; de Mello RA
    World J Gastroenterol; 2013 Oct; 19(38):6383-97. PubMed ID: 24151357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How prognostic and predictive biomarkers are transforming our understanding and management of advanced gastric cancer.
    Kim C; Mulder K; Spratlin J
    Oncologist; 2014 Oct; 19(10):1046-55. PubMed ID: 25142842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential of overcoming resistance to HER2-targeted therapies through the PI3K/Akt/mTOR pathway.
    Wilks ST
    Breast; 2015 Oct; 24(5):548-55. PubMed ID: 26187798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted therapies in gastric cancer and future perspectives.
    Yazici O; Sendur MA; Ozdemir N; Aksoy S
    World J Gastroenterol; 2016 Jan; 22(2):471-89. PubMed ID: 26811601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HER2 expression and PI3K-Akt pathway alterations in gastric cancer.
    Sukawa Y; Yamamoto H; Nosho K; Ito M; Igarashi H; Naito T; Mitsuhashi K; Matsunaga Y; Takahashi T; Mikami M; Adachi Y; Suzuki H; Shinomura Y
    Digestion; 2014; 89(1):12-7. PubMed ID: 24458107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the PI3K/Akt signaling pathway in gastric carcinoma: A reality for personalized medicine?
    Singh SS; Yap WN; Arfuso F; Kar S; Wang C; Cai W; Dharmarajan AM; Sethi G; Kumar AP
    World J Gastroenterol; 2015 Nov; 21(43):12261-73. PubMed ID: 26604635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular-targeted therapy for chemotherapy-refractory gastric cancer: a case report and literature review.
    Kuo HY; Yeh KH
    Anticancer Res; 2014 Jul; 34(7):3695-9. PubMed ID: 24982389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monoclonal antibodies-based treatment in gastric cancer: current status and future perspectives.
    Roviello G; Polom K; Petrioli R; Marano L; Marrelli D; Paganini G; Savelli V; Generali D; De Franco L; Ravelli A; Roviello F
    Tumour Biol; 2016 Jan; 37(1):127-40. PubMed ID: 26566626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advanced HER2-positive gastric cancer: current and future targeted therapies.
    Pazo Cid RA; Antón A
    Crit Rev Oncol Hematol; 2013 Mar; 85(3):350-62. PubMed ID: 23021388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.